[go: up one dir, main page]

SG11201912200YA - Method for treating a side effect of immunotherapy - Google Patents

Method for treating a side effect of immunotherapy

Info

Publication number
SG11201912200YA
SG11201912200YA SG11201912200YA SG11201912200YA SG11201912200YA SG 11201912200Y A SG11201912200Y A SG 11201912200YA SG 11201912200Y A SG11201912200Y A SG 11201912200YA SG 11201912200Y A SG11201912200Y A SG 11201912200YA SG 11201912200Y A SG11201912200Y A SG 11201912200YA
Authority
SG
Singapore
Prior art keywords
immunotherapy
treating
side effect
effect
Prior art date
Application number
SG11201912200YA
Inventor
Kilian Kelly
Igor Slukvin
Original Assignee
Cynata Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902301A external-priority patent/AU2017902301A0/en
Application filed by Cynata Therapeutics Ltd filed Critical Cynata Therapeutics Ltd
Publication of SG11201912200YA publication Critical patent/SG11201912200YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201912200YA 2017-06-16 2018-06-13 Method for treating a side effect of immunotherapy SG11201912200YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017902301A AU2017902301A0 (en) 2017-06-16 Method
PCT/AU2018/050584 WO2018227244A1 (en) 2017-06-16 2018-06-13 Method for treating a side effect of immunotherapy

Publications (1)

Publication Number Publication Date
SG11201912200YA true SG11201912200YA (en) 2020-01-30

Family

ID=64658783

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912200YA SG11201912200YA (en) 2017-06-16 2018-06-13 Method for treating a side effect of immunotherapy

Country Status (12)

Country Link
US (1) US20200323922A1 (en)
EP (1) EP3638264A1 (en)
JP (1) JP2020523400A (en)
AR (1) AR112303A1 (en)
AU (1) AU2018285953A1 (en)
BR (1) BR112019026172A2 (en)
CA (1) CA3066799A1 (en)
MX (1) MX2019014867A (en)
RU (1) RU2019143743A (en)
SG (1) SG11201912200YA (en)
TW (1) TW201920659A (en)
WO (1) WO2018227244A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004856A2 (en) 2017-09-15 2020-09-15 Cynata Therapeutics Limited method to treat allergic airway disease (aad) / asthma
KR20230098279A (en) * 2020-10-28 2023-07-03 이케나 온콜로지, 인코포레이티드 Combinations of PDX inhibitors or doxorubicin with AHR inhibitors
US20230277595A1 (en) * 2021-02-22 2023-09-07 Rohto Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent for diabetes
WO2022176735A1 (en) * 2021-02-22 2022-08-25 ロート製薬株式会社 Prophylactic and/or therapeutic agent for diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932852B2 (en) * 2009-08-14 2015-01-13 Case Western Reserve University Compositions and methods of treating inflammatory bowel disease
CA2876499C (en) * 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
MX366900B (en) * 2013-03-13 2019-07-30 Wisconsin Alumni Res Found Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions.
EP3182984B1 (en) * 2014-08-18 2019-10-30 Apceth GmbH & Co. KG Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
JP7048977B2 (en) * 2016-03-16 2022-04-06 サイナータ セラピューティクス リミテッド Colonization medium and its use
CA3008352A1 (en) * 2016-04-01 2017-10-05 Apceth Gmbh & Co. Kg Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy

Also Published As

Publication number Publication date
WO2018227244A1 (en) 2018-12-20
CA3066799A1 (en) 2018-12-20
US20200323922A1 (en) 2020-10-15
AR112303A1 (en) 2019-10-16
TW201920659A (en) 2019-06-01
MX2019014867A (en) 2020-02-13
EP3638264A1 (en) 2020-04-22
AU2018285953A1 (en) 2020-01-16
JP2020523400A (en) 2020-08-06
BR112019026172A2 (en) 2020-06-30
RU2019143743A (en) 2021-07-16

Similar Documents

Publication Publication Date Title
IL323396A (en) Method for treating cancer
IL289947A (en) Method for treating cancer
IL254393A0 (en) Methods for treating proteinopathies
PL3297975T3 (en) Method for complex treatment of phosphogypsum
IL267199A (en) Method of treating epilepsy
GB201506175D0 (en) Method of treating a material
EP3684342C0 (en) Method of treatment
PL3232811T3 (en) Method for the high-pressure treatment of a product
GB201706406D0 (en) Method of treatment
GB201815588D0 (en) Method of treatment
PL2913284T3 (en) Method and machine for treating parts
SG11201703184SA (en) A method of treatment
SG11201912200YA (en) Method for treating a side effect of immunotherapy
GB201521886D0 (en) A method of treating a well
IL248450A0 (en) Method for the surface treatment of a biocorrodable implant
GB201602802D0 (en) Method of treatment
PL3172353T3 (en) Method for treating a nitrided/nitrocarburised part
ZA201903931B (en) Method of treating meat
EP3246432A4 (en) Method for treating parts
IL266902A (en) Method for reduction of oxo-halogen compounds
GB201512055D0 (en) Method of treating a material
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment
GB201709554D0 (en) Method of treatment
GB201706642D0 (en) Method of treatment